Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Celestica Inc (CLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Celestica Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Celestica Inc trades at $338.95 (market cap $39.16B). The key difference: Celestica Inc is the larger of the two by market cap, and Celestica Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CLS | |
|---|---|---|
Market Cap | $29.60B | $39.16B |
Sector | Health | Technology |
52-Week High | $491.22 | $472.40 |
52-Week Low | $205.48 | $181.34 |
Enterprise Value | $27.56B | $39.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
CLS trades at $339.46, up 7.91% in 24 hours, with a bearish technical signal but strong fundamentals. Recent Q2 2026 EPS of $2.54 beat estimates, and revenue growth is driven by AI infrastructure demand. The company completed a $3 billion equity offering to fund expansion, though this may cause near-term dilution. Support levels are near $309, with resistance at $313.
Outlook is positive due to robust earnings beats and AI-driven growth, but risks include equity dilution and premium valuation. Analyst consensus is bullish with a $466.50 price target, indicating 37% upside. Investors should weigh growth potential against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Celestica Inc
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →
